Clinical trials: Cancer of the Thyroid
Hypothyroidism
Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer
1. The incidence of differentiated thyroid cancer is increasing in Korea. A significant number of them experience severe hypothyroidism in preparation for radioactive iodine (RAI) therapy after total thyroidectomy. 2.
- Trial name
- NCT01744769
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Konkuk University Medical Center
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Thyroid Cancer
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
The goal of the study is to evaluate a new imaging test that may allows the investigators to predict the uptake of radioactive iodine by thyroid cancer faster than the current standard and that does not interfere with the uptake…
- Trial name
- NCT03196518
- Testing
- PET Imaging, 18F-tetrafluoroborate (18F-TFB)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Nodules
Realtime-Elastography (RTE) and Thyroid Nodules
The study is an open, prospective multicenter study. According to the statistical sample size calculation 593 patients with thyroid nodules ≥ 5mm in size will be included in the study.
- Trial name
- NCT01609946
- Testing
- Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan, Cytology (FNAB) or Surgery
- Where
- 10 sites in Germany
- Volunteers
- 602 people
- Sponsor
- Johannes Vermehren
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Thyroid Cancer
Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation.
- Trial name
- NCT02156362
- Testing
- follow up visit
- Where
- France
- Volunteers
- 643 people
- Sponsor
- Hospices Civils de Lyon
Thyroid Nodule
B-mode Ultrasound, Sono-Elastography, and Diffusion-weighted Imaging MRI in Thyroid Nodules
To compare the accuracy of the conventional Ultrasound 'TI-RADS', US elastography, DWI MRI, and its ADC value in characterization and differentiation of thyroid nodules.
- Trial name
- NCT06029946
- Testing
- elastography, ultrasound
- Volunteers
- 50 people
- Sponsor
- Assiut University
Thyroid Nodules
Patients Who Underwent Thyroid Ultrasonography at Our Institution Were Selected for Shear Wave Elastography of Thyroid Nodules, and the Maximum and Mean Values of the Modulus of Elasticity of the Nodules in Transverse and Longitudinal Sections Were Analyzed.
The objective of this observational study was to evaluate the effect of transverse and longitudinal sections on the measurement of thyroid nodule stiffness by shear wave elastography.
- Trial name
- SWE (NCT06007859)
- Testing
- section orientation
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Ma Zhe
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER
Thyroid Neoplasm
Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer
Patients with a suspected thyroid nodule face an invasive and patient unfriendly diagnostic work-up to determine the risk of malignancy.
- Trial name
- NCT04883294
- Testing
- Electronic Nose
- Volunteers
- 1,500 people
- Sponsor
- Maastricht University Medical Center
Anaplastic Thyroid Cancer
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib…
- Trial name
- NCT03085056
- Testing
- Trametinib, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
DTC - Differentiated Thyroid Cancer
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated…
- Trial name
- NCT07287748
- Testing
- [211At]NaAt
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Alpha Fusion Inc.
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 2
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
- Trial name
- NCT01511393
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 6,750 people
- Sponsor
- Novo Nordisk A/S
Thyroid Gland Medullary Carcinoma
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
This trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary…
- Trial name
- NCT03892993
- Testing
- Decision Aid, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
RATIONALE: Drugs such as valproic acid may make thyroid cancers more radioiodine sensitive, which will allow for detection of tumor and make further ablation treatment effective.
- Trial name
- NCT00525135
- Testing
- Valproic Acid
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
Head and Neck Cancer
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer
RATIONALE: Radioactive iodine uses radiation to kill tumor cells. Giving iodine I 131 with or without thyroid-stimulating hormone after surgery may kill any tumor cells that remain after surgery.
- Trial name
- HiLo (NCT00415233)
- Testing
- recombinant thyroid-stimulating hormone, Radiodine ablation without rhTSH
- Where
- 25 sites in United Kingdom
- Volunteers
- 438 people
- Sponsor
- University College, London
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Papillary Thyroid Carcinoma, Thyroid Neoplasms
RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer
Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease.
- Conditions
- Papillary Thyroid Carcinoma, Thyroid Neoplasms, RET Proto-Oncogene Mutation, Lymphatic Metastasis
- Trial name
- RET-US (NCT07042984)
- Testing
- AI-Ultrasound RET Prediction
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Fujian Medical University
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.